BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Excellent results for one type of therapy were shown in the treatment of Philadelphia chromosome-positive (t(9;22)(q34;q11.2)) chronic myelogenous leukemia (CML) with imatinib as a designed drug that attacks the BCR–ABL fusion product [2,3].